Login to your account

Username *
Password *
Remember Me

Blog With Right Sidebar

Effect of CPAP on arterial stiffness in severely obese patients with obstructive sleep apnoea

Conclusion Although sleepiness and blood pressure improve with CPAP in severe obesity, CPAP alone is not sufficient to modify PWA measures to levels comparable with non-OSA patients. This supports a need for a multifaceted approach when managing cardiovascular risk in patients with severe obesity and obstructive sleep apnoea receiving CPAP therapy. (Source: Sleep and Breathing)

Strategies for Reducing the Risk of Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease

Abstract Chronic obstructive pulmonary disease (COPD) is frequently accompanied by multimorbidities in affected patients. Even though the majority of these comorbidities are also related to advanced age and cigarette smoke, also COPD itself has significant impact on insurgence, or worsening of these conditions. As a consequence, COPD is regarded as a complex disease with pulmonary and extra-pulmonary involvement. According to current guidelines for the management of COPD patients, the comprehensive treatment of this condition should target respiratory symptoms as well as comorbidities. Cardiovascular disease is one of the most frequent comorbidities in COPD patients and there are several strategies for reducing the risk of cardiovascular disease in COPD patients. These include smo...

Lung inflammatory pattern and antibiotic treatment in pneumonia

Background: In community-acquired pneumonia host inflammatory response against the causative microorganism is necessary for infection resolution. However an excessive response can have deleterious effects. In addition to antimicrobial effects, macrolide antibiotics are known to possess immunomodulatory properties.We aimed to evaluate inflammatory cytokine profiles ? both locally (bronchoalveolar lavage) and systemically (blood) ? in community-acquired pneumonia admitted patients after at least 72?hours of antibiotic treatment (with and without macrolide containing regimens) and requiring bronchoscopic examination for inadequate response due to infection progression and/or lack of clinical stability. Methods: A prospective study was performed on 52 admitted patients who developed an inadequ...

Update on Aspirin Desensitization for Chronic Rhinosinusitis with Polyps in Aspirin-Exacerbated Respiratory Disease (AERD)

Abstract Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which results in adverse upper and lower respiratory symptoms, particularly rhinitis, conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs). A provocative aspirin challenge is the gold standard for diagnosis of AERD. Aspirin desensitization and continuous aspirin therapy has been highly efficacious in those patients with suboptimal control of their disease on current available pharmacotherapy or those with other underlying conditions (i.e., cardiovascular disease) who may require frequent treatment with aspirin or NSAIDs. This review article focuses on aspirin desensitization a...

A randomised dose-ranging study of tiotropium Respimat ® in children with symptomatic asthma despite inhaled corticosteroids

Background: A considerable number of children with asthma remain symptomatic despite treatment with inhaled corticosteroids, resulting in significant morbidity, reduced quality of life, increased healthcare costs and lost school days. The aim of our study was to assess the efficacy, safety and tolerability of once-daily tiotropium Respimat? 5??g, 2.5??g and 1.25??g add-on to medium-dose inhaled corticosteroids, with or without a leukotriene modifier, in children aged 6?11 years with symptomatic asthma. Methods: In this Phase II, double-blind, placebo-controlled, incomplete-crossover, dose-ranging study, patients were randomised to receive three of the four treatments evaluated: once-daily tiotropium Respimat? 5??g, 2.5??g or 1.25??g or placebo Respimat?, in the evening during the 12-week (...

Search